Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Celltrion Posts Record-High Q1 Sales And Net Profit, Riding On Biosimilar Prospects

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's biosimilar front-runner Celltrion Inc. continued its upward swing in the first quarter of 2011with first quarter sales and net profit reaching record highs
Advertisement

Related Content

Korea’s Celltrion Initiates Clinical Trials Of Roche’s Rituxan Biosimilar
Korea’s Celltrion Initiates Clinical Trials Of Roche’s Rituxan Biosimilar
Korea's Celltrion SVP Kim Hyoung-Ki On Gearing Up To Launch Biosimilars In Global Markets: An Interview With PharmAsia News
Korea's Celltrion SVP Kim Hyoung-Ki On Gearing Up To Launch Biosimilars In Global Markets: An Interview With PharmAsia News
Celltrion Nearly Triples Production Capability For Biosimilars In Anticipation Of Global Launches
Celltrion Nearly Triples Production Capability For Biosimilars In Anticipation Of Global Launches
Korea's Celltrion Sees Growth Trend Continue On Strength Of Biosimilar Validation Batch Orders
Celltrion Pushes Back Launch Of Roche And Johnson & Johnson Biosimilars To 2012
Biosimilars Aid Korea's Celltrion To Post Record Sales And Profit In FY 2010
Biosimilars Aid Korea's Celltrion To Post Record Sales And Profit In FY 2010
Advertisement
UsernamePublicRestriction

Register

SC078142

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel